Core Insights - BioNxt Solutions Inc. announced that its German subsidiary, Vektor Pharma TF GmbH, received an "Intention to Grant" notification from the European Patent Office for a patent application related to a new formulation of cladribine [1] Company Developments - The patent application (no. 23 729 446.7) pertains to a sublingual, orally dispersible thin-film formulation of cladribine [1] - This formulation is aimed at treating multiple sclerosis (MS) and related neurodegenerative diseases [1]